Vertex Pharmaceuticals Inc. VRTX
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
What this company does
Written from the business description in VERTEX PHARMACEUTICALS INC / MA's annual report to the U.S. Securities and Exchange Commission, filed 13 February 2026. Every sentence was checked against that document before publication.
Growth
Revenue compounded at +14.1% a year over the five years to FY2025 — but profit grew slower: net income at +7.8%, earnings per share at +8.3%.
The share count fell from 0.26B to 0.25B — the buyback concentrates the same profit into fewer slices.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity produced 23 cents of profit this year.
The 18-year record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 12.0 | 11.0 | 9.9 | 8.9 | 7.6 | 6.2 | 4.2 | 3.0 | 2.5 | 1.7 | 1.0 | 0.6 | 1.2 | 1.5 | 1.4 | 0.1 | 0.1 | 0.2 |
| Operating income $B | 4.2 | −0.2 | 3.8 | 4.3 | 2.8 | 2.9 | 1.2 | 0.6 | 0.1 | 0.0 | −0.5 | −0.7 | −0.6 | 0.0 | 0.1 | −0.7 | −0.6 | −0.5 |
| EBITDA $B | 4.4 | −0.0 | 4.0 | 4.5 | 2.9 | 3.0 | 1.3 | 0.7 | 0.2 | 0.1 | −0.4 | −0.6 | −0.6 | 0.1 | 0.1 | −0.7 | −0.6 | −0.4 |
| Income tax $B | 0.7 | 0.8 | 0.8 | 0.9 | 0.4 | 0.4 | 0.2 | −1.5 | −0.1 | 0.0 | 0.0 | 0.0 | −0.1 | −0.0 | 0.0 | 0.0 | ◌ | ◌ |
| Net income $B | 4.0 | −0.5 | 3.6 | 3.3 | 2.3 | 2.7 | 1.2 | 2.1 | 0.3 | −0.1 | −0.6 | −0.7 | −0.4 | −0.1 | 0.0 | −0.8 | −0.6 | −0.5 |
| Free cash flow $B | 3.2 | −0.8 | 3.3 | 3.9 | 2.4 | 3.0 | 1.5 | 1.2 | 0.7 | 0.2 | −0.4 | −0.6 | −0.1 | 0.2 | 0.1 | −0.7 | −0.5 | −0.3 |
| EPS, diluted $ | 15.32 | −2.08 | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 | 8.09 | 1.04 | −0.46 | −2.31 | −3.14 | −1.98 | −0.50 | 0.14 | −3.77 | −3.71 | −3.27 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE % | 22.5 | −3.2 | 23.0 | 27.7 | 24.9 | 36.7 | 22.4 | 64.9 | 16.5 | −10.7 | −55.2 | −60.8 | −37.8 | −12.0 | 4.6 | −94.3 | −96.2 | ◌ |
| Shares out B | 0.25 | 0.26 | 0.26 | 0.26 | 0.25 | 0.26 | 0.26 | 0.26 | 0.25 | 0.25 | 0.25 | 0.24 | 0.23 | 0.22 | 0.21 | 0.20 | 0.20 | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 18 of the 18 fiscal years we could check. Four checks were skipped: the balance sheet is not tagged before 2009. Three checks were skipped: cost of revenue is not tagged before 2010. One check was skipped: EPS is not tagged before 2008.